Every 10-Q that Surrozen, Inc. Warrant (SRZNW) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow SRZNW and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full SRZNW filings page.
Surrozen, Inc. reported second-quarter 2026 revenue of $5.0 million, entirely from collaboration and license milestones with Boehringer Ingelheim, compared with related-party research revenue a year earlier. Research and development expense was $8.5 million and general and administrative expense $6.9 million, resulting in a loss from operations of $10.4 million. Noncash gains of $59.6 million from remeasurement of tranche and warrant liabilities and other items produced quarterly net income of $50.2 million, though the company posted a first-half 2026 net loss of $77.3 million.
Cash and cash equivalents were $102.0 million as of June 30, 2026, with $19.9 million of cash used in operations in the first half. Management believes this cash is sufficient for at least 12 months, while anticipating the need to raise additional capital to execute its long-range plan. In ophthalmology, Surrozen plans to file an IND for SZN-8141 by the end of the third quarter of 2026 and start the DUET Phase 1b/2a DME trial by year-end, with initial data expected in the second half of 2027. SZN-8143 remains in preclinical development, and Boehringer Ingelheim has advanced SZN-413 into Phase 1. Boehringer has asserted a contractual basis to reduce future milestones and royalties under the SZN-413 collaboration, which Surrozen disputes; $10.0 million of 2026 milestones have been recognized to date.
Surrozen reported a much larger net loss of $127.5 million for the three months ended March 31, 2026, driven mainly by non‑cash fair value losses on a tranche liability and warrant liabilities linked to its 2025 private placement. Revenue rose to $5.0 million, primarily from a $5.0 million research milestone earned under its collaboration with Boehringer Ingelheim. Operating expenses increased as the company advanced ophthalmology programs, including SZN‑8141 and SZN‑8143. Surrozen ended the quarter with $106.9 million in cash and cash equivalents and used $12.5 million in operating cash. It raised $26.9 million via an at‑the‑market equity program and has a contingent second PIPE tranche of about $95.1 million if the SZN‑8141 IND is cleared by the FDA by October 31, 2026, which management believes, together with current cash, can fund operations for at least the next 12 months.
Surrozen reported a cash position of $90.4 million and returned a net income of $39.7 million for the three months ended June 30, 2025, and $12.8 million for the six‑month period, driven largely by noncash fair‑value changes in a tranche liability and warrant liabilities. Operating activities used $15.4 million of cash in the first half of 2025 while the company recorded a consolidated accumulated deficit of approximately $272.5 million. In March 2025 Surrozen completed the first tranche of a two‑tranche private placement (the 2025 PIPE), raising net proceeds of about $71.2 million from the first closing and issuing 5.2 million shares, pre‑funded warrants and Series E warrants; the second tranche is contingent on FDA clearance of an IND for SZN‑8141. Warrant liabilities and a remaining tranche liability create significant noncash volatility: warrant liabilities were reported at $32.6 million and the tranche liability at $10.9 million as of June 30, 2025. Management believes existing cash is sufficient for at least 12 months, but the company expects continued R&D spending and may need additional capital to advance its pipeline.